In vitro evaluation of the PUCA II intra-arterial LVAD

The "pulsatile catheter" (PUCA) pump is a minimally invasive intra-arterial left ventricular assist device intended for acute support of critically ill heart failure patients. To assess the hydrodynamic performance of the PUCA II, driven by an Arrow AutoCat IABP driver, we used a (static) mock circulatory system in which the PUCA II was tested at different loading conditions. The PUCA II was subsequently introduced in a (dynamic) cardiovascular simulator (CVS) to mimic actual in vivo operating conditions, with different heart rates and 2 levels of left ventricular (LV) contractility. Mock circulation data shows that PUCA II pump performance is sensitive to afterload, pump rate and preload. CVS data demonstrate that PUCA II provides effective LV unloading and augments diastolic aortic pressure. The contribution of PUCA II to total flow is inversely related to LV contractility and is higher at high heart rates. We conclude that, with the current IABP driver, the PUCA II is most effective in 1:1 mode in left ventricles with low contractility.     

PUCA pump and IABP comparison: analysis of hemodynamic and energetic effects using a digital computer model of the circulation

The pulsatile catheter pump (PUCA pump) is a left ventricular assist device that provides additional flow to the left ventricle. It is usually run in order to ensure a counterpulsation effect, as in the case of the intra-aortic balloon pump (IABP). Because of this similarity, a comparison between the PUCA pump and the IABP was conducted from both the hemodynamic and energetic points of view. Numerical models of the two devices were created and connected to the CARDIOSIM cardiovascular simulator. The PUCA and IABP models were then verified using in vivo experimental data and literature data, respectively. Numerical experiments were conducted for different values of left ventricular end systolic elastance (Els) and systemic arterial compliance (Csa). The energetic comparison was conducted taking into account the diastolic pressure time index and the endocardial viability ratio. Hemodynamic results expressed as cardiac output (CO) and mean coronary blood flow (CBF) show that both the IABP and the PUCA pump efficacy decrease with higher values of Els and Csa. The IABP especially shows higher sensitivity to these parameters, to the extent that in some cases CO actually drops and CBF does not increase. On the other hand, for lower values of Csa, IABP performance improves so much that the PUCA pump flow needs to be increased in order to ensure a hemodynamic effect comparable to that of the IABP. Energetic results show a trend similar to the hemodynamic ones. The study will be continued by investigating other energetic variables and the autonomic response of the cardiovascular system.     

In vivo and in vitro experience with the PUCA-II, a single-valved pulsatile catheter-pump

The Pulsatile Catheter (PUCA) pump is a trans-arterial pulsatile ventricular assist device that can be used for short-term left ventricular support. The separate inflow and outflow valves in the first version of the device (PUCA-I) were replaced by a single inflow/outflow valve in the latest PUCA pump version (PUCA-II). The new combined valve was tested during in vitro (mock circulation) and in vivo experiments for valve leakage, flow resistance, and thrombus formation. During the in vitro experiments a maximum valve leakage of 6% during ejection and 21% during aspiration was found. The maximum flow resistance coefficient (K) was 4. The animal experiments demonstrated that the PUCA-II could be positioned within a few minutes into the left ventricle without X-ray guidance and without using a vascular graft. Thrombi were not found in the combined valve after total pump time of 3 hours, which proved the good washout of the valve. Initial experiments to position the pump in the right ventricle through the pulmonary artery were successful and contributed to the development of a new application for the device.     

Development of compact ventricular assist device for chronic use

A compact and reliable mechanical ventricular assist device is expected for chronic use. A magnetically suspended centrifugal pump (MSCP) is a seal-less, bearingless pump that can be operated for a long time with-out fear of leak or thrombus formation around the shaft. This paper reports recent progress with the MSCP, including pulse-pressure generation: In three sheep with acute heart failure induced by injection of beta-blockers, left ventricular assist was instituted with an inflow cannula into the left atrium (LA) and left ventricle (LV), and the outflow cannula to the descending aorta. The timing of the pulsation was synchronized with the electrocardiogram. Cardiac performance was evaluated by a conductance catheter and a tipped manometer in the LV. As pump speed increased, the pump flow became almost continuous. After application of pulsation, the pulse pressure increased from 5 to 25 mmHg, irrespective of the inflow cannulation site and the timing of pulsation. With LA cannulation, LV pressure at copulsation was slightly higher than at counterpulsation. Chronic animal trial: The MSCP was implanted in three sheep. The inflow cannula was inserted into the LV. The native heart was kept intact. The inner surface was coated with heparin. Continuous hemodynamic monitoring as well as periodic blood sampling was performed. The duration of running of the pump was 60, 140, and 248 days. The causes of termination were infection and failure of magnetic suspension due to electrical short. No thrombus or embolic findings were observed in the whole body after sacrifice. Renal and hepatic functions were within normal range throughout the experiment. It is concluded that the MSCP can produce pulsation irrespective of the inflow cannulation site and timing of synchronization. It is a promising device for chronic ventricular support.     

Development of acute ischemic heart failure in sheep

The goal of the present study was to develop a large animal model of acute ischemic left ventricular heart failure (LVHF) that can be used to assess the influence of the PUCA pump on the heart and circulatory system under realistic conditions. We tested the hypothesis that mild stenosis of the coronary artery in combination with mild ventricular pacing induces an acute heart failure condition, whereas the separate phenomena themselves do not lead to impaired heart function. Mean aortic pressure (AoP), left ventricular end-diastolic pressure (LVEDP), stroke volume (SV) and myocardial systolic shortening (MSS) were compared 30 minutes after a pacemaker (PM) induced tachycardia in anaesthetized sheep (n=3) without and with +/- 50% stenosis of the proximal LCx. All parameters measured restored to basic levels when stenosis was absent. When the LCx was partially occluded, mild PM-induced tachycardia resulted in decreased AoP (P=0.045) as well as in decreased SV (P=0.048); the LVEDP remained high (P=0.002). Also the recovery of MSS was impaired when stenosis was present (P=0. 002). These values indicate that acute heart failure conditions were present. The technique used proved to be safe and allowed fine-tuning of the demand ischemia by adapting heart frequency to the required heart failure conditions. The model can be used to study the effect of LV mechanical support during acute heart failure conditions.     

A pulsatile control algorithm of continuous-flow pump for heart recovery

The intra-aorta pump is a novel continuous flow (CF) left ventricular (LV) device. According to literatures, the pulsatile flow LV device can provide superior LV unloading and circulatory support compared with CF LV assist devices at the same level of ventricular assist device flow. Therefore, a pulsatile control algorithm for the intra-aorta pump is designed. It can regulate the pump to generate pulsatile arterial pressure (AP) and blood flow. A mathematic model of the cardiovascular-pump system is used to verify the feasibility of the control strategy in the presence of LV failure. The surplus hemodynamic energy (SHE), pulsatile ratio (PR), and pulsatile attenuation index (PAI) are used to evaluate the pulsatility of AP and blood flow. The SHE is 8,012.0 ergs/cm(3) by using the pulsatile control strategy (PCS) compared with 5,630.0 ergs/cm(3) by failing heart without support. The PR is 0.302 in the PCS vs. 0.315 in failing heart without support. Meanwhile, the PAI is 85.9% in the PCS compared with 69.7% in failing heart without support. The results demonstrate that the presented control strategy can maintain the pulsatility of AP and blood flow. Moreover, the pulsatile controller provides notably LV unloading. To test the response of the controller to the change of blood demand of patients, another simulation is conducted. In this simulation, the peripheral resistance is reduced to mimic the status of a slight physical active; the Emax is increased to simulate the ventricular contractility recovery. The simulation results demonstrate that the proposed control strategy can automatically regulate the pump in response to the change of the parameters of the circulatory system. To test the dynamic character of the intra-aorta pump, an in vitro experiment is conducted on an in vitro experiment rig. The experimental results demonstrate that the intra-aorta pump can achieve the pulsatile pump speed calculated by the pulsatile controller. The PCS is feasible for the intra-aorta pump. As a key feature, the proposed control strategy provides adequate perfusion in response to the change of blood demands of patients, while restoring the pulsatility of AP and blood flow.     

Pitfalls in the development of a rotary blood pump controller

The controller presents a major obstacle in the development of the rotary blood pump as a left ventricular assist device (LVAD). Clinically, LVAD flow is a good indicator in the regulation of circulatory conditions and pump flow changes, depending on pump preload and afterload. Many investigators have tried estimating pump flow by referencing the motor current. There have been pitfalls in in vitro experimental settings, however. Using a test loop with a pneumatically driven LV chamber and a centrifugal pump as an LVAD, we monitored pump flow and pressure head to evaluate the pump performance curve (H-Q curve). Under pulsatile LV conditions, the H-Q curve was a loop that changed, depending on LV contractility. The pneumatically driven LV chamber cannot mimic the Starling phenomenon, so the developed LV pressure does not change according to the LV preload. Rotary pump flow estimation is the most effective control method. In pulsatile conditions, however, the H-Q curve is a loop that changes under various LV contractility conditions, complicating determination of linear equation for calculating flow. In addition, the LV chamber in the test loop cannot mimic native heart contractility as described by Starling's law. This finding can lead to a misanalysis of the H-Q curve under pulsatile conditions.     

Development of "plug and play" TransApical to aorta VAD

Our TransApical to Aorta pump, a simple and minimally invasive left ventricular (LV) assist device, has a flexible, thin-wall conduit connected by six struts to a motor with ball bearings and a turbine extending into the blood path. Pulsatile flow is inherent in the design as the native heart contraction preloads the turbine. In six healthy sheep, the LV apex was exposed by a fifth intercostal left thoracotomy. The pump was inserted from the cardiac apex through the LV cavity into the ascending aorta. Aortic and LV pressure waveforms, pump flow, motor current, and pressure were directly measured. All six cannula pumps were smoothly advanced on the first attempt. Pump implantation was <15 minutes (13.6 +/- 1.8 minutes). Blood flow was 2.8 l/min to 4.4 l/min against 86 +/- 8.9 mm Hg mean arterial blood pressure at maximum flow. LV systemic pressure decreased significantly from 102.5 +/- 5.55 mm Hg to 58.8 +/- 15.5 mm Hg at the fourth hour of pumping (p = 0.042), and diastolic LV pressure decreased from 8.4 +/- 3.7 to 6.1 +/- 2.3 mm Hg (p > 0.05). The pump operated with a current of 0.4 to 0.7 amps and rotation speed of 28,000 to 33,000 rpm. Plasma free hemoglobin was 4 +/- 1.41 mg/dl (range, 2 to 5 mg/dl) at termination. No thrombosis was observed at necropsy.A left ventricular assist device using the transapical to aorta approach is quick, reliable, minimally invasive, and achieves significant LV unloading with minimal blood trauma.     

Patient-specific finite element modeling of the Cardiokinetix Parachute® device: effects on left ventricular wall stress and function

The Parachute^® (Cardiokinetix, Inc., Menlo Park, California) is a catheter-based device intended to reverse left ventricular (LV) remodeling after antero-apical myocardial infarction. When deployed, the device partitions the LV into upper and lower chambers. To simulate its mechanical effects, we created a finite element LV model based on computed tomography (CT) images from a patient before and 6 months after Parachute^® implantation. Acute mechanical effects were determined by in silico device implantation (VIRTUAL-Parachute). Chronic effects of the device were determined by adjusting the diastolic and systolic material parameters to better match the 6-month post-implantation CT data and LV pressure data at end-diastole (ED) (POST-OP). Regional myofiber stress and pump function were calculated in each case. The principal finding is that VIRTUAL-Parachute was associated with a 61.2 % reduction in the lower chamber myofiber stress at ED. The POST-OP model was associated with a decrease in LV diastolic stiffness and a larger reduction in myofiber stress at the upper (27.1 %) and lower chamber (78.4 %) at ED. Myofiber stress at end-systole and stroke volume was little changed in the POST-OP case. These results suggest that the primary mechanism of Parachute^® is a reduction in ED myofiber stress, which may reverse eccentric post-infarct LV hypertrophy.     

In vitro hemodynamic evaluation of ventricular suction conditions of the EVAHEART ventricular assist pump

Purpose: Mismatches between pump output and venous return in a continuous-flow ventricular assist device may elicit episodes of ventricular suction. This research describes a series of in vitro experiments to characterize the operating conditions under which the EVAHEART centrifugal blood pump (Sun Medical Technology Research Corp., Nagano, Japan) can be operated with minimal concern regarding left ventricular (LV) suction. Methods: The pump was interposed into a pneumatically driven pulsatile mock circulatory system (MCS) in the ventricular apex to aorta configuration. Under varying conditions of preload, afterload, and systolic pressure, the speed of the pump was increased step-wise until suction was observed. Identification of suction was based on pump inlet pressure. Results: In the case of reduced LV systolic pressure, reduced preload (=10 mmHg), and afterload (=60 mmHg), suction was observed for speeds =2,200 rpm. However, suction did not occur at any speed (up to a maximum speed of 2,400 rpm) when preload was kept within 10-14 mmHg and afterload =80 mmHg. Although in vitro experiments cannot replace in vivo models, the results indicated that ventricular suction can be avoided if sufficient preload and afterload are maintained. Conclusion: Conditions of hypovolemia and/or hypotension may increase the risk of suction at the highest speeds, irrespective of the native ventricular systolic pressure. However, in vitro guidelines are not directly transferrable to the clinical situation; therefore, patient-specific evaluation is recommended, which can be aided by ultrasonography at various points in the course of support.     

Reduction of the susceptibility to infective endocarditis with time in animals with endocavitary catheters.

In a previous study we showed that the lesions of non-bacterial thrombotic endocarditis induced by means of implantation of a catheter in the left ventricle (LV) of the rabbit, undergo inner connectivization and surface endothelialization, which are completed within 2-3 months. In the present study we have investigated whether these histological changes lead to a variation in susceptibility to infective endocarditis (IE). After studying two control groups, we compared the incidence of IE in four groups of 15 rabbits each, inoculated with Streptococcus mitis I, 10, 35 and 70 days after implantation of a catheter in the LV. The frequency of infection was shown to be progressively reduced from 100% to 26.7%. This demonstrates that endothelialization of the catheter and the sterile vegetations protect the animals from IE.     

Reduction of the susceptibility to infective endocarditis with time in animals with endocavitary catheters

In a previous study we showed that the lesions of non-bacterial thrombotic endocarditis induced by means of implantation of a catheter in the left ventricle (LV) of the rabbit, undergo inner connectivization and surface endothelialization, which are completed within 2-3 months. In the present study we have investigated whether these histological changes lead to a variation in susceptibility to infective endocarditis (IE). After studying two control groups, we compared the incidence of IE in four groups of 15 rabbits each, inoculated with Streptococcus mitis I, 10, 35 and 70 days after implantation of a catheter in the LV. The frequency of infection was shown to be progressively reduced from 100% to 26.7%. This demonstrates that endothelialization of the catheter and the sterile vegetations protect the animals from IE.     

Off-resonance positive contrast imaging of a passive endomyocardial catheter in swine

The use of off-resonance methods in interventional MRI may be valuable since active devices that provide positive signal enhancements are currently not approved for human use. This study investigated the capacity of a low flip angle steady-state free precession (FLAPS) method for generating off-resonance positive contrast surrounding a susceptibility-shifted endomyocardial Stiletto catheter in excised swine hearts and in live swine. Consistent with theory, discernable positive contrast surrounding the interventional device was visualized under ex-vivo (CNR of 24 +/- 2.1 in the left ventricular (LV) chamber and 18 +/- 2.7 in LV myocardium) and in-vivo conditions (CNR of 22 +/- 3.9 in aorta, 16 +/- 4.1 in the LV chamber and 13 +/- 0.9 in LV myocardium). The findings show that off-resonance imaging with the FLAPS method may be used for passive device visualization with positive contrast. Further studies are necessary prior to clinical translation.     

Device based left ventricular shape change: validation of conductance technology in shape changed hearts

We have reported that device based left ventricular (LV) shape change, accomplished by Myosplint, improved LV systolic function by three-dimensional echocardiography (3-D echo). However, evaluation of this device using the pressure-volume relationship is still important. This study was conducted to validate the use of conductance technology for this evaluation in shape-changed hearts. An ex vivo study using excised ovine hearts (n = 11) and an in vivo study using a canine pacing-induced heart failure model (n = 11) were performed. Three Myosplints were implanted. Before and after the shape changes, volumes measured by a conductance catheter were compared with volumes measured by the amount of saline in the ex vivo study or by 3-D echo in the in vivo study. The conductance volumes were linearly correlated with the saline volumes (r2 = 0.961+/-0.046; p < 0.0001) in the ex vivo study and with 3-D echo volumes (r2 = 0.757+/-0.220; p < 0.0001) in the in vivo study. The conductance volumes were linearly correlated with LV volumes even in the shape-changed hearts. This technology can be used to evaluate pressure-volume loops in the shape-changed hearts as long as the conductance volume is calibrated by a reliable method.     

Analysis of the relationship between left ventricular pressure and motor current for evaluation of native cardiac function during left ventricular support with a centrifugal blood pump

Control of the ventricular assist device (VAD) for native heart preservation should be attempted, and the VAD could be one strategy for dealing with the shortage of donors in the future. In the application of nonpulsatile blood pumps for ventricular assistance from the ventricular apex to the aorta, bypass flow and hence the motor current of the pumps change in response to the ventricular pressure change. Utilizing these intrinsic characteristics of the continuous-flow pumps, in this study we investigated whether motor current could be used as an index for continuous monitoring of native cardiac function. In study 1, a centrifugal blood pump (CFP) VAD was installed between the apex and descending aorta of a mock circulatory loop. In this model, a baseline with a preload of 10 mmHg, afterload of 40 mmHg, and LV systolic pressure of 40 mmHg was used. The pump speed was fixed at 1300, 1500, and 1700 rpm, and LV systolic pressure was increased up to 140 mmHg by steps of 20 mmHg while the changes in LV pressure, motor current, pump flow, and aortic pressure were observed. In study 2, an in vivo experiment was performed using three sheep. A left heart bypass model was created using a centrifugal pump from the ventricular apex to the descending aorta. The LVP was varied through administration of dopamine while the changes in LV pressure, pump flow, and motor current at 1500 and 1700 rpm were observed. An excellent correlation was observed in both in vitro and in vivo studies in the relationship between motor current and LV pressure. In study 1, the correlation coefficients were 0.77, 0.92, and 0.99 for 1300, 1500, and 1700 rpm, respectively. In study 2, they were 0.88 (animal no. 1), 0.83 (animal no. 2), and 0.88 (animal no. 3) for 1500 rpm, and 0.95 (animal no. 2) and 0.93 (animal no. 3) for 1700 rpm. These results suggest that motor current amplitude monitoring could be useful as an index for the control of VAD for native heart preservation.     

Simulation of systolic and diastolic left ventricular dysfunction in a mock circulation: the effect of arterial compliance

Arterial compliance (AC) is expected to play a major role on cardiac efficacy by acute or long-term mechanisms. The aim of this study was to investigate the purely mechanical effect of AC on left ventricular (LV) performance, for different conditions of LV dysfunction (systolic versus diastolic). A hydraulic, Windkessel model of systemic circulation was used. LV function and aortic flow were simulated using a left ventricular assist device (LVAD). Two cases of LV dysfunction were simulated: Case A, systolic and Case B, diastolic dysfunction. In Case A, AC increased from 1.14 to 2.85 ml mm Hg(-1) leading to an increase in LVAD stroke volume up to 6%, while no significant effect was observed in Case B. LVAD systolic work was decreased by 4% in systolic and by 11% in diastolic LVAD dysfunction. The purely mechanical effect of AC changes on LVAD function was different between systolic and diastolic dysfunction. It might be expected that even an acute reduction in arterial stiffness could enhance LV performance by different means in systolic compared to diastolic dysfunction.     

心肌梗塞后泵功能的恢复及其机制的实验研究

造成大鼠不同范围的心肌梗塞(MI)后,动态观察不同时期的静息和容量负荷状态下泵功能恢复的规律及其代偿机制。结果证明:(1)梗塞范围(IS)小于左室的46%时,泵功能都有自动恢复的可能性。IS越小,恢复越快、越好。IS超过46%时未见恢复;(2)在IS相同的条件上,静息状态的泵功能远较负荷状态的泵功能恢复得好;(3)MI后,泵功能代偿机制的代偿效应与IS呈反比。如IS超过46%,任何代偿机制均难以发挥效应。     

Simulation of systolic and diastolic left ventricular dysfunction in a mock circulation: the effect of arterial compliance

Arterial compliance (AC) is expected to play a major role on cardiac efficacy by acute or long-term mechanisms. The aim of this study was to investigate the purely mechanical effect of AC on left ventricular (LV) performance, for different conditions of LV dysfunction (systolic versus diastolic). A hydraulic, Windkessel model of systemic circulation was used. LV function and aortic flow were simulated using a left ventricular assist device (LVAD). Two cases of LV dysfunction were simulated: Case A, systolic and Case B, diastolic dysfunction. In Case A, AC increased from 1.14 to 2.85 ml mm Hg &#109 1 leading to an increase in LVAD stroke volume up to 6%, while no significant effect was observed in Case B. LVAD systolic work was decreased by 4% in systolic and by 11% in diastolic LVAD dysfunction. The purely mechanical effect of AC changes on LVAD function was different between systolic and diastolic dysfunction. It might be expected that even an acute reduction in arterial stiffness could enhance LV performance by different means in systolic compared to diastolic dysfunction.     

The enabler cannula pump: a novel circulatory support system.

BACKGROUND: The enabler circulatory support system is a catheter pump which expels blood from the left or right ventricular cavity and provides pulsatile flow in the ascending aorta or pulmonary artery. It is driven by a bedside installed pulsatile driving console. The device can easily be implanted by a minimal invasive approach, similar to the Hemopump. PURPOSE: To demonstrate the hemodynamic performance of this new intracardiac support system. METHODS: In a series of 9 sheep, hemodynamic evolutions were recorded in various conditions of myocardial contractility (the non-failing, the moderately failing and the severely failing heart). Heart failure was induced by injection of microspheres in the coronary arteries. RESULTS: Introduction of the cannula through the aortic valve was feasible in all cases. Pump flow by the enabler was gradually increased to a maximum of 3.5 L/min. Diastolic (and mean) aortic blood pressure is significantly increased in the non-failing and moderately failing condition (counterpulsation mode). In heart failure, cardiac output is significantly increased by the pump (p < 0.0001). A drop in left atrial pressure (indicating unloading) is achieved in all conditions but reaches significant levels only during heart failure (p=0.0068). CONCLUSIONS: This new circulatory support system contributes to stabilization of the circulation in the presence of cardiac unloading. In heart failure it actually supports the circulation by increasing cardiac output and perfusion pressure.